<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id>
      <journal-title-group>
        <journal-title>Annals of Hematology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0939-5555</issn>
      <issn pub-type="epub">1432-0584</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20625901</article-id>
      <article-id pub-id-type="pmc">3052470</article-id>
      <article-id pub-id-type="publisher-id">1026</article-id>
      <article-id pub-id-type="doi">10.1007/s00277-010-1026-x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>T-cell prolymphocytic leukaemia: spontaneous immunophenotypical switch from CD4 to CD8 expression</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Tse</surname>
            <given-names>Eric</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>So</surname>
            <given-names>Chi-Chiu</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cheung</surname>
            <given-names>Winnie W. W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kwong</surname>
            <given-names>Yok-Lam</given-names>
          </name>
          <address>
            <phone>+852-2255-5859</phone>
            <fax>+852-2974-1165</fax>
            <email>ylkwong@hkucc.hku.hku</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>FRCPath, Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China </aff>
        <aff id="Aff2"><label>2</label>Department of Pathology, Queen Mary Hospital, Hong Kong, China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>7</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>13</day>
        <month>7</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2011</year>
      </pub-date>
      <volume>90</volume>
      <issue>4</issue>
      <fpage>479</fpage>
      <lpage>481</lpage>
      <history>
        <date date-type="received">
          <day>6</day>
          <month>6</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>6</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2010</copyright-statement>
      </permissions>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>A 48-year-old man was incidentally found to have a lymphocytosis, with haemoglobin: 14.1&#xA0;g/dL, white cell count: 16.6&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L (77% abnormal lymphocytes), and platelet count: 160&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L. The abnormal lymphocytes were small, with scanty basophilic cytoplasm showing frequent blebs (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>). The nuclei contained condensed chromatin and inconspicuous nucleoli. They were predominantly positive for CD4 (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>), and expressed CD2, CD5, CD7 and T cell receptor (TCR) &#x3B1;&#x3B2;. Karyotyping showed inv(14)(q11q32) with multiple karyotypic aberrations (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). Serologic test for human T-lymphotropic virus 1 was negative. The diagnosis was consistent with T-prolymphocytic leukaemia (T-PLL) [<xref ref-type="bibr" rid="CR1">1</xref>]. The patient elected not to receive treatment. Eight months afterwards, he presented with erythematous rashes, generalised lymphadenopathy and splenomegaly. A full blood count showed haemoglobin: 10.9&#xA0;g/dL, white cell count: 132&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L (95% abnormal lymphocytes), and platelet count: 139&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L. Interestingly, the lymphocytes showed a diminution in CD4, but an increase in CD8 expression (CD4+CD8&#x2013;:23.9%, CD4&#x2013;CD8+: 65.5%, CD4+CD8+: 10.6%; Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref>). Skin biopsy confirmed leukaemic infiltration. The patient was treated with alemtuzumab (30&#xA0;mg/day thrice weekly) for 4&#xA0;weeks without response. Two courses of fludarabine, mitoxantrone, dexamethasone [<xref ref-type="bibr" rid="CR2">2</xref>] and resumption of alemtuzumab were ineffective. Immunophenotyping 11&#xA0;months after diagnosis showed that the PLL cells were predominantly CD8 expressing (CD4&#x2013;CD8+:73.5%, and CD4+CD8+:25.8%; Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1e</xref>). Owing to the poor response to alemtuzumab, CD52 expression was investigated. The PLL cells had retained CD52 expression (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1f</xref>). To investigate if a new clone might have emerged, polymerase chain reaction for TCR gamma gene was performed. Identical peaks were demonstrated despite a change from CD4 to CD8 expression (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1g</xref>). Splenectomy was performed, followed by combination chemotherapy (dexamethasone, methotrexate, ifosphamide, etoposide, L-asparaginase). However, the patient died of sepsis 2&#xA0;weeks afterwards.
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Pathological features of a case of T-cell prolymphocytic leukemia (PLL). <bold>a</bold> Abnormal lymphoid cells at diagnosis, showing condensed nuclei with inconspicuous nucleoli, and scanty basophilic cytoplasm with frequent blebs (Wright&#x2013;Giemsa stain, original magnification &#xD7;100). <bold>b</bold> Flow cytometric analysis at diagnosis, showing predominance of CD4+ PLL cells. <bold>c</bold> Karotyping analysis, showing inv(14)(q11q32) (<italic>arrow, insert</italic>) and other aberrations. <bold>d</bold> At 8&#xA0;months, there was an increase in CD8+ PLL cells. <bold>e</bold> At 11&#xA0;months, there was predominance of CD8+ PLL cells. <bold>f</bold> CD52 expression had been consistent through the clinical course. <bold>g</bold> T cell receptor gene gamma rearrangement studies, showing identical peaks at various time points in the clinical course (GeneMapper v3.7, Applied Biosystems)</p></caption><graphic xlink:href="277_2010_1026_Fig1_HTML" id="MO1"/></fig></p>
    <p>This case showed a number of interesting features pertinent to the diagnosis of T-PLL. The usual morphological features of prolymphocytes, viz., small to medium cells with a single distinct nucleolus and abundant cytoplasm, were not observed. The neoplastic cells were instead mature looking. It has been proposed that a diagnosis of &#x201C;mature T cell leukaemia, unclassified&#x201D; might be offered to such cases [<xref ref-type="bibr" rid="CR3">3</xref>]. However, had the case presented later when CD8 expression predominated, a diagnosis of T cell large granular lymphocyte leukaemia might have been entertained. These diagnostic difficulties were resolved with demonstration of inv(14), implying that this case should be classified as the small cell variant of T-PLL [<xref ref-type="bibr" rid="CR1">1</xref>]. The immunophenotypical switch from CD4 to CD8 was also intriguing. Molecular analysis confirmed that the CD4 to CD8 switch occurred in the same clone, implying that the immunophenotypical switch was an intrinsic property of the T-PLL cells. This phenomenon appeared to be exceptionally rare; and to our knowledge, only one similar case had been reported, in which a change from CD4 to CD8 expression was associated with large cell transformation [<xref ref-type="bibr" rid="CR4">4</xref>]. Interestingly, the CD8+ phenotype had also been reported to be associated with a poor response to conventional chemotherapy [<xref ref-type="bibr" rid="CR5">5</xref>]. Such observations were recapitulated in our case, which showed a relentless deterioration with increasing CD8 expression.</p>
  </body>
  <back>
    <ack>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Catovsky</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Muller-Hermelink</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Ralfkiaer</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Swerdlow</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Thiele</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vardiman</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>T-cell prolymphocytic leukemia</article-title>
          <source>WHO classification of tumours of haematopoietic and lymphoid tissues</source>
          <year>2008</year>
          <publisher-loc>Lyon</publisher-loc>
          <publisher-name>International Agency for Research on Cancer</publisher-name>
          <fpage>270</fpage>
          <lpage>271</lpage>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Au</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Chim</surname>
              <given-names>CS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients</article-title>
          <source>Br J Haematol</source>
          <year>2004</year>
          <volume>124</volume>
          <fpage>754</fpage>
          <lpage>761</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2004.04852.x</pub-id>
          <pub-id pub-id-type="pmid">15009063</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Foucar</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sezary syndrome</article-title>
          <source>Am J Clin Pathol</source>
          <year>2007</year>
          <volume>127</volume>
          <fpage>496</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="doi">10.1309/KWJYBCCGTB90B6AE</pub-id>
          <pub-id pub-id-type="pmid">17369126</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kubota</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Suda</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Morphological and immunological change in the predominant type of leukaemic cells in a patient with T-cell chronic lymphocytic leukaemia</article-title>
          <source>Scand J Haematol</source>
          <year>1986</year>
          <volume>36</volume>
          <fpage>439</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0609.1986.tb02278.x</pub-id>
          <pub-id pub-id-type="pmid">3488584</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matutes</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brito-Babapulle</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Swansbury</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia</article-title>
          <source>Blood</source>
          <year>1991</year>
          <volume>78</volume>
          <fpage>3269</fpage>
          <lpage>3274</lpage>
          <pub-id pub-id-type="pmid">1742486</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
